An international study involving researchers from UBC Okanagan has shown that MDMA, also known as ecstasy, may be a valuable tool for treating post-traumatic stress disorder (PTSD).
Published recently in Psychopharmacology, the study demonstrated substantial improvements in individuals who had not responded to prior treatments, explains UBCO Associate Professor of Psychology Zach Walsh. This is also, he adds, the most comprehensive evaluation of the safety and effectiveness of MDMA-assisted psychotherapy for PTSD.
“PTSD symptoms decreased after one session of MDMA together with psychotherapy,” says Walsh, study co-author. He adds that 54 per cent of participants no longer met PTSD criteria after two sessions and that there was also improvement in their symptoms of depression.
The response of participants to MDMA-assisted psychotherapy was compared to those who received small doses or non-drug psychotherapy.
“These findings are promising and indicate the needed for larger studies,” says Walsh. “Too many people with PTSD struggle to find effective treatment, and use of MDMA in a supportive environment with trained mental health professionals could be an important addition to our treatment options.”
Ecstasy, also known as Molly, is the nickname for MDMA—a synthetic drug made from a combination of methylenedioxy-methamphetamine. It is a controlled, illegal drug in Canada classified as a stimulant with hallucinogenic properties.
Walsh, as well as researchers from the United States, Switzerland and Israel, examined the results from six clinical trials, involving 103 people. Trial participants included men and women with chronic, treatment-resistant PTSD from a wide variety of causes.
Based on these results, the US Food and Drug Administration granted breakthrough therapy designation to MDMA-assisted psychotherapy for PTSD, acknowledging that it “may demonstrate substantial improvement over existing therapies” and agreeing to expedite its development and review.
The first of two more in-depth clinical trials of MDMA-assisted psychotherapy for PTSD began enrolling participants in November 2018 and aims to have 100-150 volunteers across 15 sites in the US, Canada, and Israel. The second trial will take place after an interim analysis of the data from the first trial, and will enrol an additional 100-150 participants. European trials are planned to start in the near future.
Nearly four per cent of all people worldwide will suffer from PTSD during their lifetime. PTSD can be a debilitating disorder, with symptoms including intrusive thoughts and memories, negative effects on thinking and mood, depression, hyperarousal and reactivity, and avoidance. People with PTSD can experience much lower quality of life and relationships, related mental health conditions and suicidal tendencies.
The Latest on: PTSD treatment
via Google News
The Latest on: PTSD treatment
- 'Didn't think I was going to make it': Raleigh man suffers from PTSD after two COVID-19 hospitalizationson October 7, 2020 at 4:08 pm
"Just being left in that dark room. It brings back thoughts. Not knowing if you're going to make it. You have the chills. The night sweats, you're sore, you're tossing and turning," Leroy Windley said ...
- PTSD In Teens: Helping Adolescents Cope and Deal with PTSDon October 7, 2020 at 2:34 pm
The events that cause PTSD, or Post Traumatic Stress Disorder, are as varied as the people who struggle with it, including teens.
- Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybinon October 7, 2020 at 4:40 am
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a ...
- 'Brain fog' following COVID-19 recovery may indicate PTSDon October 7, 2020 at 1:10 am
A new report suggests that lingering "brain fog" and other neurological symptoms after COVID -19 recovery may be due to post-traumatic stress disorder (PTSD), an effect observed in past human ...
- ‘Brain fog’ following Covid-19 recovery may indicate PTSD: Studyon October 7, 2020 at 12:10 am
A new report suggests that people who recover from Covid-19 infection may experience “brain fog” and other neurological symptoms due to post-traumatic stress disorder (PTSD), an effect observed in ...
- "Brain fog" after COVID -19 recovery may indicate post-traumatic stress disorderon October 6, 2020 at 9:56 pm
A new report suggests that lingering "brain fog" and other neurological symptoms after COVID-19 recovery may be due to post-traumatic stress disorder (PTSD), an effect observed in past human ...
- 'Brain fog' following COVID-19 recovery may indicate PTSD, says Studyon October 6, 2020 at 8:44 pm
People who have recovered from COVID-19 sometimes experience lingering difficulties in concentration, as well as headaches, anxiety, fatigue or sleep ...
- 'Brain fog' following Covid-19 recovery may indicate post-traumatic stress disorder: Studyon October 6, 2020 at 7:35 pm
People who have recovered from COVID-19 sometimes experience lingering difficulties in concentration, as well as headaches, anxiety, fatigue or sleep disruptions.Patients may fear that the infection ...
- First responders urgently push for PTSD coverage at Ohio state capitolon October 6, 2020 at 12:54 pm
The Ohio FOP has been fighting for the state’s laws to change. Right now, workers' compensation doesn’t cover PTSD treatment unless the first responder has a physical injury that caused it. Wolske ...
- Researchers streamline PTSD diagnosis with machine learningon September 30, 2020 at 8:04 am
Post-traumatic stress disorder (PTSD) affects eight million adults in the US, including hundreds of thousands of veterans of the conflicts in Iraq and Afghanistan. And as the COVID crisis continues to ...
via Bing News